Our analyses’ findings are important because reducing ApoB levels and the cholesterol content across all the spectrum of ApoB lipoproteins (in addition to LDL-C) represents an opportunity to address the residual ASCVD risk that still exists in many patients with T2DM despite normal LDL-C levels and receiving optimal statin therapy [20]. The gene discussed is APOB; the disease is atherosclerosis.